The article is devoted to an urgent problem of modern neurology - early diagnosis and complex restorative treatment of cerebral palsy (cerebral palsy). Etiological factors and pathogenetic aspects of the formation of various forms of cerebral palsy are considered in detail, as well as modern possibilities of differential diagnosis in children of the first years of life of cerebral palsy and a wide range of pathological conditions (somatic, endocrine, hereditary-conditioned, including hereditary-metabolic and neuromuscular diseases). The leading directions of complex rehabilitation of cerebral palsy are widely presented, taking into account modern standards and clinical recommendations. The high efficacy of the drug Cortexin has been shown, due to its positive multimodal action (stimulation of the processes of neuropreparation, neuroprotection, neuroplasticity) in the treatment of motor, cognitive and autonomic disorders in children with perinatal lesions of the central nervous system and cerebral palsy.

2024-01-01·S.S. Korsakov Journal of Neurology and Psychiatry

Post-stroke cognitive impairment in young patients

Article

作者: Gribacheva, I A ; Rerikh, K V ; Boznyakov, A.V. ; Popova, T F ; Taneeva, E.V. ; Popova, T.F. ; Sokolova, D V ; Rerikh, K.V. ; Boznyakov, A V ; Shchepankevich, L.A. ; Gribacheva, I.A. ; Shchepankevich, L A ; Taneeva, E V ; Tyazhelnikov, N.E. ; Sokolova, D.V. ; Tyazhelnikov, N E

OBJECTIVETo evaluate the effect of Cortexin treatment on cognitive function and quality of life for young patients after ischemic stroke.MATERIAL AND METHODSThe open prospective observational study included 30 patients from 18 to 45 years old with confirmed ischemic stroke in the carotid blood supply who received a course of treatment with Cortexin. Before and after therapy, all patients in the study group underwent examination to assess their neuropsychological status (MoCA test), The Short Form-36 (SF-36) questionnaire was used to assess quality of life. The study results were processed using statistical analysis.RESULTSBased on the results of neurocognitive tests, changes in indicators of neurodynamic, visual-spatial and mnestic functions were determined. Thus, in the beginning of the study the MoCA test scores were 25.1±1.4 points. Over time, there was an improvement mainly in the areas of attention, short-term memory, and multiple aspects of executive functions. However, statistical significance for MoCA was achieved by the end of the second course of treatment with Cortexin (visit 4) - 28.4±1.3 points. Delayed neuropsychological testing showed encouraging results - the achieved level of cognitive functioning was maintained (28.0±1.1). According to SF-36 questionnaire at the stage of inclusion in the observation, low results were noted, which indicated the negative impact of the underlying disease on the daily life of the patient who had suffered a stroke. Low quality of life scores persisted until the third visit; a significant improvement in SF-36 results was recorded at visit 4 and persisted with a positive trend at the fifth visit.CONCLUSIONCortexin therapy has been shown to be effective, safe and well tolerated in young people with cognitive deficits in the poststroke period.

2024-01-01·S.S. Korsakov Journal of Neurology and Psychiatry

Neuprotection of post-acute COVID-19 cognitive impairment

Article

作者: Melnik, E A

OBJECTIVETo evaluate the efficacy of Cortexin in the treatment of patients with post-Covid impairment.MATERIAL AND METHODSTreatment results of 109 patients with post-Covid cognitive impairment aged from 42 to 65 years were analyzed. The main group (MG, n=52), 29 (55.8%) men and 23 (44.2%) women, average age 58.1±4.9 years, who received Cortexin continuously for 20 days at a dose of 10 mg i.m., after 3, 6 months. The comparison group included 57 people, 31 (54.4%) men and 26 (45.6%) women (average age 59.3±3.8 years). The effectiveness of therapy was assessed using neuropsychological testing with international scales.RESULTSDuring treatment, statistically significant differences were obtained in MG patients in the form of improved concentration (p<0.05), increased control of exutative functions (p<0.05), and auditory-verbal memory (p=0.002). There were no adverse events in the MG.CONCLUSIONCortexin is highly effective and safe, and can be recommended as part of a combined staged therapy for post-Covid cognitive impairment. Thus, the study confirms the feasibility of using Cortexin, which has a neurocytoprotective effect.

100 项与 Neuroprotective peptide(Geropharm LLC) 相关的药物交易

登录后查看更多信息